Patent intelligence · US
US 12319916
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
Patent details — US 12319916
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 3, 2025
- Expiration
- May 29, 2045
- Applicant
- CAMP4 Therapeutics Corporation
- Claims
- 15
- CPC classes
- A61P, A61P13/00
Quick answer
US 12319916 (Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAMP4 Therapeutics Corporation
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61P, A61P13/00
More from CAMP4 Therapeutics Corporation
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12319916?
US 12319916 (Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs) is held by CAMP4 Therapeutics Corporation. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12319916?
CAMP4 Therapeutics Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12319916 expire?
Our index shows an expiration date of May 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.